ZyVersa Therapeutics, Inc. (ZVSA) has announced new data showing that its Inflammasome ASC Inhibitor IC 100 significantly improves heart function, reduces inflammation, and restores glucose homeostasis in an obese animal model of heart failure with preserved ejection fraction or HFpEF and type 2 diabetes.
The data highlights the potential of IC 100 as a promising treatment for obesity-related cardiovascular and metabolic diseases.
The study found that IC 100 reduced cardiac inflammation, improved diastolic heart function, and decreased fat mass and adipocyte size.
It also enhanced insulin sensitivity and glucose regulation, positioning IC 100 as a therapeutic candidate for HFpEF and its comorbidities.
The research supports ZyVersa's ongoing efforts to leverage IC 100 in treating metabolic complications associated with obesity.
Currently, ZVSA is trading at $1.06 up by 1.45 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.